Search

Your search keyword '"Safety pharmacology"' showing total 659 results

Search Constraints

Start Over You searched for: Descriptor "Safety pharmacology" Remove constraint Descriptor: "Safety pharmacology" Topic business.industry Remove constraint Topic: business.industry
659 results on '"Safety pharmacology"'

Search Results

1. Current Trends of Practices in Nonclinical Toxicology: An Industry Survey

2. Safety assessment of HEA‐enriched Cordyceps cicadae mycelia on the central nervous system (CNS), cardiovascular system, and respiratory system in ICR male mice

4. The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators

5. An Integrative Approach for Improved Assessment of Cardiovascular Safety Data

6. Acute and Subchronic Toxicities and Safety Pharmacology Studies of a Bacillus Subtilisin in Dogs

7. Risk–efficacy balance of ulipristal acetate compared to surgical alternatives

8. Non-clinical toxicology evaluation of BIA 10-2474

9. Chronic cardiotoxicity assessment of BMS-986094, a guanosine nucleotide analogue, using human iPS cell-derived cardiomyocytes

10. Technology and evaluation best practices for in vivo cardiovascular safety pharmacology studies

11. Are older adults insufficiently included in clinical trials?—An umbrella review

12. Nonclinical Studies that Support Viral Vector-Delivered Gene Therapies: An EFPIA Gene Therapy Working Group Perspective

13. Safety pharmacology assessment of Ethanamizuril, a novel triazines coccidiostat

14. Safety Pharmacology Study of Medicines Used for Febrile Syndrome Management in Children

15. What is considered cardiotoxicity of anthracyclines in animal studies Corrigendum in /10.3892/or.2020.7717

16. Blinded, Multicenter Evaluation of Drug-induced Changes in Contractility Using Human-induced Pluripotent Stem Cell-derived Cardiomyocytes

17. Evaluating Associations Between Nonclinical Cardiovascular Functional Endpoints and Repeat-dose Cardiovascular Toxicity in the Beagle Dog: A Cross-company Initiative

18. Safety Pharmacology Evaluation of Biopharmaceuticals

19. Monitoring of Cardiorespiratory Parameters in Rats—Validation Based on Pharmacological Stimulation

20. Application of the Pluripotent Stem Cells and Genomics in Cardiovascular Research—What We Have Learnt and Not Learnt until Now

21. Healthy volunteers in first-in-human oncology drug development for small molecules

22. [Cardiovascular safety pharmacology: in vitro strategies and improvements in technology and evaluation]

23. 18th Annual Meeting of the Safety Pharmacology Society: drug safety assessment on gastrointestinal system functions

24. Quality Standards of Preclinical Pharmacological Studies

25. The influence of hERG1a and hERG1b isoforms on drug safety screening in iPSC-CMs

26. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications

27. Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals

28. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence

29. Pharmacological safety of Plinia cauliflora (Mart.) Kausel in rabbits

30. Safety assessment of subtilisin QK in rats

31. 124-LB: Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes

32. Improved nonclinical safety profile of a novel, highly selective inhibitor of the immunoproteasome subunit LMP7 (M3258)

33. Safety Pharmacology Study of ET-26 Hydrochloride, a Potential Drug for Intravenous General Anesthesia, in Rats and Beagle Dogs

34. Inflammation as a Risk Factor in Cardiotoxicity: An Important Consideration for Screening During Drug Development

35. The canine chronic atrioventricular block model in cardiovascular preclinical drug research

36. Plant-Based Traditional Herbal Contraceptive Use in India: Safety and Regulatory Issues

38. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma

40. Role of the rabbit whole-heart model for electrophysiologic safety pharmacology of non-cardiovascular drugs

41. 1920-P: First Oral MC4R Agonist for the Treatment of Rare Genetic Obesity

42. Is there a role for the no observed adverse effect level in safety pharmacology?

43. An Industry Survey With Focus on Cardiovascular Safety Pharmacology Study Design and Data Interpretation

44. Dual Transcriptomic and Molecular Machine Learning Predicts all Major Clinical Forms of Drug Cardiotoxicity

45. Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective

46. Evaluation of genetic toxicity, acute and sub-chronic oral toxicity and systemic safety of Agrimonia pilosa and Rhus gall 50% ethanolic extract mixture (APRG64) in vitro and in vivo (rodent and non-rodent animal models)

47. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products)

48. Intensive care for human hearts in pluripotent stem cell models

49. Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment

50. Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models

Catalog

Books, media, physical & digital resources